Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham
Research funding in oncology, autoimmune, and CNS disease areas
CAMBRIDGE, MA — Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), announced a Sponsored Research Agreement with Mass General Brigham. With more than 80,000 employees, 13 Nobel laureates and an annual research budget of $2 billion, Mass General Brigham is one of the largest and most prestigious academic medical centers in the United States. Under the agreement up to eight research groups at Mass General Brigham will be funded on select projects over the course of two years.
The agreement aims to establish a mutually beneficial partnership that will advance scientific research and create new treatment options for patients with cancer, autoimmune, and CNS diseases. By partnering with Mass General Brigham, Simcere gains access to cutting-edge research and leading clinical capabilities which will help accelerate the company’s global R&D efforts. In return, this collaboration will support the biopharma community by providing additional resources for medical research and clinical trials.
“We believe that this Sponsored Research Agreement with Mass General Brigham represents a significant step forward in our efforts to develop innovative new treatment options for patients around the world,” said Zhou Gaobo, chief investment officer, Simcere Pharmaceutical Group. “This partnership underscores our commitment to advancing drug development and building long-term partnerships that benefit not only Simcere but also the broader medical community and ultimately, the patients.”
“The discoveries resulting from this agreement could further advance potentially game-changing technology to the front lines of care in three areas of rapid clinical advancement and high patient need — neurology, oncology, and inflammation and immunology,” said Chris Coburn, chief innovation officer at Mass General Brigham. “We’re excited to collaborate with industry partners, such as Simcere, whose expanding presence in the Boston area is reflective of our region’s continued growth as a biotech hub.”
The presence of Simcere’s Boston Innovation Center (BIC) in the Cambridge area will provide opportunities for local collaboration and partnerships, leading to further synergies between participating research groups. Additionally, Simcere’s Project X, which aims at providing highly talented scientist with funding and employment, will further contribute to the local medical research community.
Overall, the Sponsored Research Agreement with Mass General Brigham, announced at the World Medical Innovation Forum 2023 in Boston, is an exciting development for Simcere and represents a substantial step forward in the company’s efforts to further enhance its global R&D capabilities and develop innovative therapeutics for patients around the world.
In separate announcement today, Simcere Pharmaceutical Group also announced the company is continuing its global footprint as Zaiming has established a subsidiary, Simcere Zaiming, Inc., in Massachusetts, USA.
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group Limited (2096.HK) is an innovation and R&D-driven pharmaceutical company. The Company focuses on three therapeutic areas, oncology, neurology and autoimmune diseases, with a forward-looking vision toward disease areas that have substantial clinical needs , aiming to achieve the mission of “providing today’s patients with medicines of the future.” Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D and commercial stage collaborations have made it a strategic alliance partner with world leading innovative companies and research institutes. For more information, please visit: http://en.simcere.com/
Forward-Looking Statements
This press release contains certain “forward-looking statements” concerning financial and operating plans and results which involve known and unknown risks and uncertainties. In particular, statements preceded or followed by, or that include the words, “projects,” “believes,” “expects,” “estimates,” “anticipates,” “plans,” “intends,” “scheduled,” or similar expressions are forward-looking statements. Various factors could cause Mass General Brigham’s actual results to differ materially including, but not limited to the impact of the COVID-19 pandemic, federal and state regulation of healthcare providers, changes in reimbursement policies of state and federal government and managed care organizations, competition in the healthcare industry in our market, general economic and capital market conditions, and changes in our labor and supply costs and in our ability to retain personnel. For more information on these and other risk factors, please refer to our most recent bond official statement or annual disclosure statement filed on the Electronic Municipal Market Access (EMMA) website maintained by the Municipal Securities Rulemaking Board. We undertake no responsibility to update any such forward-looking statements except as expressly required by law.